Aurobindo Pharma reported a 6% year-on-year increase in consolidated revenue, reaching ₹8,286 crores for Q2 FY26. EBITDA stood at ₹1,678 crores, with a margin of 20.3%, reflecting a 7% year-on-year growth. The company’s formulation business grew by 10%, contributing 88% of total revenue, driven by strong performance in the U.S., Europe, and key growth markets. The company expects to sustain growth momentum and drive value creation across all businesses.
Financial Performance
Aurobindo Pharma announced its financial results for the second quarter of fiscal year 2026, highlighting a 6% year-on-year increase in consolidated revenues, which reached ₹8,286 crores. This growth signifies the sustained business momentum throughout the first half of FY26.
The company’s EBITDA for the quarter stood at ₹1,678 crores, representing a margin of 20.3%, and demonstrating a 7% year-on-year growth. This performance reflects operating leverage, cost efficiency, and disciplined execution.
Business Segment Highlights
The formulation business reported a year-on-year growth of 10%, with revenues reaching ₹7,325 crores, contributing approximately 88% of the total consolidated revenues. This growth was primarily driven by strong performance in the U.S., Europe, and key growth markets.
U.S. revenues stood at $417 million. Excluding gRevlimid, the U.S. Oral Solid business delivered a healthy 6% quarter-on-quarter growth.
The European business maintained strong growth, delivering 18% year-on-year revenue growth, amounting to ₹2,480 crores. Aurobindo expects to comfortably surpass the 1 billion annual revenue milestone from Europe by the end of FY26.
Revenue from growth markets increased by 9% year-on-year to ₹882 crores, driven by strong volume growth.
Operational Updates
The Pen-G plant commenced operations on July 1, 2025, and produced around 1,050 MT during the quarter, operating at 40%-50% capacity.
Future Outlook
Aurobindo Pharma remains confident in sustaining its growth momentum and driving value creation across all businesses. This optimism is underpinned by expected volume expansion and a reasonably stable pricing environment. The company expects to deliver an internal margin target of 20%-21% for FY26.
Source: BSE
